Naprod Life Sciences

What Naprod Life Sciences does

Naprod Life Sciences Pvt. Ltd. is a privately held Indian specialty pharmaceutical manufacturer founded in 1994 by Shri Babulal K. Jain and incorporated in 2006. Headquartered in Mumbai with a state-of-the-art manufacturing facility at Tarapur/Boisar (Maharashtra), the company focuses on oncology, anti-neoplastic, anesthesia, and general injectable formulations. It is one of the pioneers in India in lyophilization (freeze-drying) technology for injectable pharmaceuticals, with specific expertise in lyophilized cytotoxic oncology injectables, sterile solutions, anticancer injectables, and emulsion/micro-emulsion formulation. The company is vertically integrated through its wholly-owned API subsidiary Macchem, supporting self-sufficiency from active ingredient through finished formulation, and operates an additional adjacent subsidiary, Samrudh Pharma, for cephalosporins, critical care, anesthesia, and veterinary products. Production capacity includes 3.5 million units/year of oncology lyophilized powder, 3 million units/year of oncology liquid injectables, 30 million tablets/year, 15 million capsules/year, and a combined 11 million units/year of general injectables, across a portfolio of more than 500 products.

The company generates revenue through four streams: direct product sales of specialty formulations, contract manufacturing (CDMO/CMO) for pharmaceutical companies, contract research and development services, and dossier out-licensing in emerging markets. It supplies Indian government, semi-government, and private healthcare institutions through a direct marketing network; serves UK and European pharmaceutical companies via CMO agreements and out-licensing of EU GMP-certified products; and operates co-marketing partnerships across South-East Asia, Africa, Russia/CIS, and Latin America. Its facilities carry EU GMP, WHO GMP, TGA (Australia), ANVISA (Brazil), INVIMA (Colombia), PICS (Malaysia), BPOM (Indonesia), DIGEMID (Peru), and multiple African national regulatory certifications, enabling market access across four continents.

The business is founder-owned with no public listing or external institutional investors evidenced. Leadership comprises Founder Chairman Shri Babulal K. Jain and Director Mr. Mohan B. Jain. Recent material developments include a 2025–2026 production halt of cisplatin and carboplatin due to platinum price surges and Indian government price caps, an unresolved 2020 contamination incident in Colombia involving contaminated methotrexate, and a current eight-product development pipeline targeting targeted oncology therapies (Abiraterone, Ruxolitinib, Ibrutinib, Palbociclib) and complex injectables (Liposomal Doxorubicin, Liposomal Irinotecan, Sugammadex, Brivaracetam).

Name

Naprod Life Sciences

Legal name

Naprod Life Sciences Pvt. Ltd.

Website

https://naprodgroup.com

Company type

Private

Founded year

1994

Operating status

Operating

Headcount range

251–500 employees

Short description

Naprod Life Sciences is an Indian specialty pharmaceutical manufacturer producing oncology, anesthesia, and general injectable formulations using proprietary lyophilization technology. It serves Indian healthcare institutions, international pharma partners through CDMO services, and emerging markets via dossier out-licensing across four continents.

Ownership category

akta.pro rank

Product category

Oncology Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Lyophilization (Freeze-Drying) CDMO (HLAGABAI)

akta.pro secondary industries

Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• Pharmaceutical manufacturing
• Oncology formulations
• Anesthesia injectables
• Lyophilized injectables
• Contract manufacturing services

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Product Sales - Oncology & Anesthesia Formulations: Naprod manufactures and sells specialty pharmaceutical formulations in oncology and anesthesia segments, serving domestic Indian market and international markets across Asia, Europe, Latin America, and Africa through direct sales and distribution partnerships.
2. Contract Manufacturing (CDMO/CMO): Provides end-to-end manufacturing services including formulation development, analytical method development and validation, small scale and commercial scale production. Partners include pharmaceutical companies requiring manufacturing capabilities for regulated markets.
3. Contract Research & Development: Labs equipped for formulation and analytical development, including stability studies, method development and validation. Services support projects from formulation to finished products with QCD (Quality, Cost and Delivery) approach.
4. Dossier Licensing (Out-licensing): Naprod has developed scores of dossiers approved by regulators from different countries available for out-licensing in emerging markets, enabling partners to commercialize approved products.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels4 records

Core offering

Naprod Life Sciences manufactures and supplies specialty pharmaceutical formulations with a primary focus on oncology/anti-neoplastic injectable and oral products (including Cisplatin, Carboplatin, Oxaliplatin, Paclitaxel, Docetaxel, Imatinib, Everolimus, Pazopanib) and anesthesia formulations (Propofol, Atracurium, Rocuronium, Ketamine, Lignocaine, Midazolam). The company operates EU GMP and WHO GMP-certified facilities, leveraging lyophilization (freeze-drying) technology for stable injectable oncology products, and produces solid oral dosage forms (tablets and capsules), liquid injectables, and lyophilized powders. Beyond branded product sales, Naprod offers CDMO/CMO contract manufacturing, contract R&D, and dossier out-licensing services to pharmaceutical companies globally.

Product overview

Naprod Life Sciences is a pharmaceutical company offering a diversified portfolio of specialty formulations organized into multiple sub-brands and product categories. The core offering includes Anti-neoplastic/Oncology Formulations (54+ chemotherapy drugs including platinum-based agents like Cisplatin and Carboplatin, taxanes, and targeted therapies), Anesthesia Formulations (injectable anesthetic and neuromuscular blocking agents including Propofol), and General Formulations (antibiotics, proton pump inhibitors, and critical care injectables). Products are distributed through Naprod ROW Products (rest-of-world markets), Naprod SRA Products (stringent regulatory authority markets like EU/UK), and Samrudh Pharma (cephalosporins, critical care, veterinary). The company operates as both a CDMO/CMO offering contract manufacturing services from API through finished formulations, and as a supplier of generic pharmaceuticals. Manufacturing capabilities include lyophilized injectables, liquid injectables, and solid oral dosage forms (tablets/capsules) at EU GMP-certified facilities.

Differentiator

Problem solved

Functional benefit

Brands

• Samrudh: General formulations brand including Cephalosporins, Critical Care Range, Anesthesia and Veterinary products

Products and services

• Anti-neoplastic Formulations (Oncology Portfolio)

Quantifiable outcome

• Oncology Lyophilized Powder for injection capacity: 3.5 Million/Year; Oncology Liquid Injectables: 3 Million/Year; Solid Oral Dosage: 30 Million Tablets/Year + 15 Million Capsules/Year; General Injectables: 11 Million/Year total

Named customers3 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Macchem (Group Company)coreStrategic or Co-development PartnerMacchem is part of the Naprod group of companies and provides API manufacturing capabilities. This vertical integration enables Naprod to have self-sufficiency in Active Pharmaceutical Ingredients, supporting formulation manufacturing from upstream to finished products. The partnership provides competitive, high quality, custom end-to-end manufacturing services from API manufacturing through formulation development, analytical method development and validation, to commercial scale production.
• Samrudh PharmacoreStrategic or Co-development PartnerSamrudh Pharma collaborates with Naprod Team for manufacturing Cephalosporins, Critical Care Range, Anesthesia and Veterinary range products. This partnership extends Naprod's product portfolio in general formulations beyond its core oncology and anesthesia focus areas, with Naprod providing technical and quality expertise.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Syngene International: Indian contract research and manufacturing organization (CRO/CDMO) offering development and manufacturing services to global pharma. Comparable on contract research and development services arm, though focused more on biologics and small molecules than sterile injectables.

Direct peers

• Natco Pharma: Indian specialty pharma with strong oncology and complex generics franchise, including oncology APIs and finished formulations. Comparable in product portfolio composition (oncology focus, niche specialty injectables) and export orientation to regulated and emerging markets.
• Piramal Pharma Solutions: India-focused CDMO offering sterile fill-finish, lyophilization, and complex injectable manufacturing services for global pharma. Direct CDMO peer to Naprod's contract manufacturing business, particularly on lyophilized injectables and oncology manufacturing partnerships.
• Intas Pharmaceuticals: Indian pharmaceutical company with strong oncology and biosimilars franchise, plus contract manufacturing and global presence including UK/EU and emerging markets. Comparable on oncology injectables, biosimilars pipeline, and CDMO services orientation.
• Shilpa Medicare: Indian pharmaceutical company with significant CDMO/CMO operations and oncology API/formulations focus. Closely comparable to Naprod on the oncology injectables + CDMO + lyophilization axis, serving similar global markets including regulated and emerging geographies.
• Hetero Drugs: Indian vertically integrated pharma with API and formulations across oncology, antivirals, and generics. Comparable vertical integration model (API through finished dosage), CDMO offerings, and emerging market focus including Africa.

Broad incumbents

• Cadila Healthcare (Zydus): Indian pharmaceutical major with oncology, injectables, and global generics business including African and emerging market presence. Comparable in oncology injectables manufacturing and multi-jurisdictional regulatory strategy.
• Aurobindo Pharma: Large Indian generic pharmaceutical manufacturer with oncology, antibiotics, and injectable product portfolios. Operates EU GMP facilities with global distribution; broader and larger scale than Naprod but directly comparable on oncology injectables and global market reach.
• Cipla: Major Indian pharmaceutical company with oncology, anesthesia, and respiratory portfolios. Directly comparable on anesthesia injectables (propofol, neuromuscular blockers) and oncology product overlap, though at substantially larger scale.
• Dr. Reddy's Laboratories: Indian pharma major with significant oncology and injectable franchise, plus CDMO services. Comparable on oncology injectables, global regulatory footprint, and CDMO business model, though at much larger scale than Naprod.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/Naprod

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Naprod Life Sciences